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Abstract: Travoprost is a prostaglandin analog used in the management of glaucoma and ocular 
hypertension for reducing intraocular pressure (IOP). The IOP-lowering efficacy of travoprost has 
been shown to be similar to that of other prostaglandins, including latanoprost and bimatoprost. 
When compared with fixed combinations of timolol and either latanoprost or dorzolamide, travoprost 
alone can reduce mean IOP in a similar or superior manner. Concomitant therapy of travoprost and 
timolol can reach even greater IOP reductions than fixed combinations at some time points, but with 
no difference in the early morning, when IOP is usually higher. In addition, the long duration of 
action of travoprost can also provide better control of IOP fluctuation, probably due to its stronger 
prostaglandin F receptor mechanism. The side effects of travoprost do not represent a risk to the 
vision or health of the patient. The proven efficacy and safety combined with convenient once-daily 
dosing for travoprost increases patient compliance with treatment for glaucoma.
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Introduction
Glaucoma is an optic neuropathy usually associated with increased intraocular pressure 
(IOP) that causes progressive visual field loss. This disease is one of the main causes of 
blindness worldwide.1 Although several risk factors are associated with glaucoma onset 
and progression, the presence of high levels of IOP is the most important risk factor and 
the only one that can be changed.2 Reduction of IOP is the most efficient and clinically 
accepted therapy to avoid deterioration of optic disc and progression of visual loss.3
Fortunately, topical medications for lowering IOP have shown good efficacy and 
safety in glaucoma and ocular hypertension patients.4 There are five categories of topi-
cally administered medications available for the treatment of glaucoma, ie, cholinergic 
agents, adrenergic agonists, carbonic anhydrase inhibitors, β-adrenoceptor antagonists, 
and prostaglandin analogs (PGAs).6,7 PGAs and β-adrenoceptor antagonists are the 
most frequently used topical medications for reducing IOP in patients with glaucoma.8 
Moreover, PGAs are the most effective drugs to reduce IOP, with fewer systemic side 
effects, and requiring only a single drop daily. Currently, the PGAs have been found 
to be more effective than β-blockers in the reduction of IOP in patients with glaucoma 
and ocular hypertension.9,10
Travoprost acid, the biologically active form of travoprost, is a prostaglandin F2a 
analog and a fully selective agonist to the prostaglandin F receptor.11–14 This receptor 





PGAs reduce IOP by increasing the outflow of aqueous 
humor through the uveoscleral pathway.15,16
However, if treatment with monotherapy fails to reduce 
or maintain IOP under control, a fixed combination can be 
an alternative to keep daily single-drop therapy.4 Combining 
drugs that have different modes of action should provide an 
additional IOP lowering effect.11,16
It is known that inadequate compliance with glaucoma 
therapy is a risk factor for progression of the disease and 
blindness. Several guidelines indicate that adequate glau-
coma therapy requires a high level of compliance and this 
can be better achieved with lower frequency of use of ocular 
  medications.7 The Ocular Hypertension Treatment study 
found that, after five years of therapy, about 40% of patients 
required two or more medications to control IOP from base-
line of 20% and a final IOP of ,24 mmHg. A number of 
studies have found poor compliance in more than one-third 
of patients with glaucoma (depending on the therapy used),2 
and compliance is further compromised by increasing age.4
Rossi et al used an electronic device, ie, the Travatan 
Dosing Aid, in a six-month cohort study to assess adherence 
in glaucoma patients under travoprost or travoprost-timolol 
therapy. Even with single-drop therapy, only 30.3% of 
patients had perfect adherence. The major causes of noncom-
pliance were advancing age and duration of therapy.5
In this scenario, a fixed combination administered once 
daily may offer better and more convenient treatment for 
patients with glaucoma or ocular hypertension than the 
concomitant administration of two medications.4,16
Usually, medical therapy is the first-choice procedure to 
treat primary open-angle glaucoma and some patients with 
ocular hypertension.17 However, when medical therapy with 
topical agents fails to lower IOP, laser and more invasive sur-
gical procedures are needed to reduce the risk of progressive 
visual field loss in patients with initial or advanced primary 
open-angle glaucoma and the development of a defect in 
patients with ocular hypertension.2,3,18
Efficacy
Travoprost has been compared with several drugs, especially 
timolol and fixed combinations of timolol. This kind of compar-
ison has an important clinical impact because of the widespread 
use of timolol and timolol fixed combinations worldwide.
Goldberg et al randomized 573 patients with open-
angle glaucoma or ocular hypertension to treatment with 
two different concentrations of travoprost, ie, 0.0015% and 
0.004% once daily or to treatment with timolol maleate 0.5%. 
The enrolled subjects had untreated IOP of at least 24 mmHg, 
with a mean IOP among all subjects of approximately 
26 mmHg. After nine months of treatment, mean IOP 
averaged across six study visits was lower with travoprost 
0.004% than with timolol 0.5% at all time points. Mean IOP 
reductions ranged from 8.0 to 8.9 mmHg with travoprost 
0.004% versus 6.3 to mmHg with timolol 0.5%.10
Figueiredo et al compared IOP reduction and the effect 
on ocular blood flow between travoprost, latanoprost, 
bimatoprost, and unoprostone in 92 patients with open-angle 
glaucoma or ocular hypertension without previous treatment. 
After three months, travoprost and bimatoprost showed a 
similar 7.2 mmHg IOP reduction, whereas latanoprost and 
unoprostone showed 6.9 mmHg and 1.6 mmHg reductions, 
respectively. It was shown that travoprost could also increase 
pulsatile ocular blood flow.19
Parrish et al compared three PGAs head-to-head in a 
randomized, 12-week prospective trial including 410 subjects. 
This group reported no differences in mean IOP reduction 
between travoprost (8.0 mmHg), latanoprost (8.7 mmHg), 
and bimatoprost (8.6 mmHg, P = 0.128).20
In another study, Cantor et al compared the efficiency of 
travoprost and bimatoprost treatment in 157 patients over six 
months at different time points. The mean IOP reductions 
with travoprost and bimatoprost were, respectively, 5.7 versus 
7.1 mmHg at 9 am (P = 0.014), 5.2 versus 5.9 mmHg at 1 pm 
(P = 0.213), and 4.5 versus 5.3 mmHg at 4 pm (P = 0.207). 
IOP reductions $20% and $30% were achieved by statisti-
cally similar proportions of patients as revealed by responder 
analysis, and both groups presented statistically equivalent 
investigator-determined clinical success which was based on 
drug tolerability and achievement of target IOP.21
Franks et al studied the IOP-lowering response of patients 
with open-angle glaucoma or ocular hypertension treated with 
travoprost and a fixed combination of latanoprost 0.005% and 
timolol 0.5%. In this study, 110 subjects were randomized to 
receive either travoprost once daily in the evening or latanoprost-
timolol once daily in the morning and, depending on randomiza-
tion, masking was achieved by use of a placebo in the morning. 
IOP reduction between the two groups showed no statistically 
significant difference at any time point in the study. Travoprost 
lowered IOP by 7.0 mmHg and latanoprost-timolol by 
6.4 mmHg in the morning and, at the end of the day, IOP 
reductions were 6.8 and 6.1 mmHg, respectively.11
Suzuki Jr et al compared travoprost and the fixed 
combination of dorzolamide 2% and timolol 0.5% on relative 
IOP reduction. In a study that was masked to investigators 
but not to subjects, 56 patients with open-angle glaucoma 
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travoprost once daily in the evening or dorzolamide-timolol 
twice daily. A statistically significant lower mean IOP was 
observed with travoprost than with dorzolamide-timolol 
(P , 0.01) across all visits and time points. The mean IOP 
with travoprost ranged from 7.1 to 7.5 mmHg, compared 
with 4.5 to 4.8 mmHg with dorzolamide-timolol at three 
and six weeks. In addition, more complaints were reported 
by patients in the dorzolamide-timolol group.22
In conclusion, the most relevant studies comparing 
travoprost with other drugs showed similar IOP reductions 
with travoprost and with latanoprost or bimatoprost. More-
over, travoprost showed similar or superior results when 
compared with fixed combinations of timolol with either 
latanoprost or dorzolamide.
Effect on IOP fluctuation
Because circadian IOP variability has emerged as an 
independent risk factor for the progression of glaucoma, the 
circadian IOP-lowering profiles of medications have become 
a relevant measure of their clinical efficacy.23,24   Considering 
this, the endurance of travoprost`s IOP effect periods ranging 
from 24 to 84 hours postdose have been evaluated by several 
studies.16,17
Orzalesi et al compared the 24-hour IOP-lowering profiles 
of travoprost, latanoprost, and bimatoprost in a crossover study. 
Sequential treatment with each of the three drugs for one month 
(with a one-month washout between each treatment) was given 
to 44 subjects with primary open-angle glaucoma or ocular 
hypertension. The patients had 24-hour IOP assessments at 
baseline and at the end of each month-long treatment session. 
The mean circadian IOP (measured in the sitting position using 
Goldmann applanation tonometry) between the three drugs 
showed no statistically significant difference. Mean circadian 
IOP reduction of travoprost was 7.1 mmHg, compared with 
6.7 mmHg for latanoprost and 7.9 mmHg for bimatoprost 
(P = 0.08). Knowing that supine IOP is generally higher than 
sitting IOP, another relevant aspect of a drug`s IOP-lowering 
profile is the ability to lower IOP in the supine position, ie, 
while asleep at night). In order to measure supine IOP they also 
used an electronic tonometer, and no differences in circadian 
IOP reduction between the three drugs were observed.25
Garcia-Feijoo et al undertook a prospective, randomized, 
double-masked trial to compare the duration of action 
of travoprost and latanoprost in 62 patients with primary 
open-angle glaucoma or ocular hypertension. During 
14 days, the patients received once-daily treatment at 8 pm, 
and then sitting and supine IOP assessments using Perkins 
tonometry were made every four hours out to 48 hours after 
drug administration. In the first and second 24-hour periods 
after the last dose, the mean IOPs produced by travoprost 
in the sitting position were lower than for latanoprost, but 
this was not statistically significant. On the other hand, IOP 
was significantly lower in the travoprost group at every IOP 
measurement for 12, 16, 20, 24, 36, 40, and 48 hours after the 
last dose in the supine position. Mean travoprost IOPs from the 
periods 0–24, 24–48, and 0–48 hours postdosing were lower 
than for latanoprost in the supine position (P , 0.05).26
Taking these studies together, it becomes clear that 
the duration of action of travoprost exceeds its 24-hour 
dosing period, and that reductions from baseline are seen 
up to 63 hours after the last dose. At the end of each dosing 
period, travoprost, which is labeled for dosing once daily in 
the evening, has been shown to provide better IOP control 
when compared with latanoprost.16,25,26
When a stronger dose is needed  
for glaucoma control
Almost one half of glaucoma patients on topical treatment 
require more than one drug to control IOP, and patient com-
pliance with glaucoma treatment is clearly affected when 
multiple drops are needed. Fixed combinations can be an 
alternative to maintain adequate IOP control and improve 
compliance.16,22 Schuman et al in a prospective, randomized, 
double-masked, multicenter trial compared a fixed combi-
nation once daily in the morning with concomitant therapy 
using travoprost once daily in the evening and timolol twice 
daily in 403 subjects with open-angle glaucoma or ocular 
hypertension during three months. The results showed 
that at every visit and time point, the IOP-lowering from 
baseline was greater with the fixed combination than with 
timolol monotherapy. On the other hand, significantly bet-
ter IOP reduction from baseline at two of nine time points 
was observed with concomitant dosing of the separate com-
ponents, while equivalent reductions were observed at the 
remaining seven time points. IOP reductions for the fixed 
combination, travoprost and timolol concomitant therapy, 
and timolol from baseline measured across the visits and 
time points were 6.8–8.6 mmHg, 7.3–8.4 mmHg and 
4.6–7.0 mmHg, respectively.27
In another prospective, randomized, multicenter, double-
masked trial, Hughes et al also compared the fixed combination 
dose once daily in the morning with the concomitant admin-
istration of travoprost once daily in the evening and timolol 
once daily in the morning in 316 subjects with open-angle 
glaucoma or ocular hypertension over three months. They 





not inferior to concomitant dosing, inasmuch as at seven of 
nine time points, the upper 95% confidence limit for the dif-
ference in mean IOP between the two treatment groups was 
within ± 1.5 mmHg. The two time points that were an excep-
tion to this both occurred in the morning and on separate visits. 
The fixed-combination IOP reductions from baseline were 
7.4–9.4 mmHg and for travoprost and timolol concomitant 
therapy were 8.4–9.4 mmHg.28
It can be concluded from these studies that there is better 
efficiency with concomitant therapy rather than with the com-
bination at several time points. The different dosing protocols, 
in which the prostaglandin is given in the morning in the fixed 
combination group and in the evening in the concomitant group, 
might influence this finding because evening dosing of prosta-
glandins rather than morning dosing is generally recommended. 
Therefore, the occasional transient conjunctival hyperemia 
that follows topical dosing tends to have lesser clinical signifi-
cance. In contrast, because of the natural reduction of aqueous 
humor production at night, beta-blockers are more effective for 
  lowering IOP with morning dosing rather than with evening dos-
ing. Therefore, the fixed combination with timolol could have 
better performance as a result of the morning dosing.16,29,30
In order to understand better the efficacy of the 
  travoprost-timolol fixed combination when dosed in the 
morning versus evening, Denis et al evaluated 92 subjects 
with open-angle glaucoma or ocular hypertension in a 
prospective, randomized, double-masked trial. The fixed 
combination either in the morning or in the evening was 
given to patients for six weeks. The results were similar in 
the morning group and in the evening group, and their IOP 
reductions ranged from 16.5 to 16.7 mmHg and from 16.1 
to 17.2 mmHg, respectively. The 8–10 mmHg (32%–38%) 
IOP reductions from baseline of were statistically significant 
and clinically relevant in both groups.31
Pfeiffer et al assessed the safety and efficacy of changing 
to the travoprost-timolol fixed combination from other 
monotherapies or adjunctive therapies in 472 patients with 
uncontrolled or below-target glaucoma therapy. After three 
months, the travoprost-timolol fixed combination reduced 
IOP from the level prior to treatment by 5.6 (± 2.6) mmHg. 
Ocular hyperemia was the most frequent adverse effect 
(n = 21, 4%). Both patients and physicians preferred the 
travoprost-timolol fixed combination compared with all prior 
and common individual treatments.32
Adding other drugs to travoprost
The effects of adding topical carbonic anhydrase inhibitors 
or topical alpha-agonists to PGAs remains little explored.33 
It has been shown that dorzolamide is more effective than 
timolol or brimonidine 0.2% as adjunctive therapy for 
lowering IOP in eyes already on latanoprost.34
In another double-masked crossover trial, Konstas et al 
could not find any difference in 24-hour IOP measurements 
between adjunctive dorzolamide twice daily and brimonidine 
0.15% twice daily in combination with latanoprost after six 
weeks of adjunctive therapy.
The mean baseline IOP of the 79 patients was 22.5 
(15–31) mmHg. Four weeks later, the mean IOP of the 78 
patients under treatment with a combination of travoprost 
and brinzolamide was 18.5 (12–24) mmHg. Finally, 12 weeks 
later, the mean IOP for 71 evaluable patients was 18.2 
(10–27) mmHg. At all time points, IOP was significantly 
reduced when compared with baseline values (P , 0.0001). 
The average IOP had decreased by 3.9 mmHg (17.4%) after 
four (n = 78) and by 4.2 mmHg (18.4%) after 12 (n = 71) 
weeks of combined travoprost and brinzolamide therapy 
when compared with the monotherapy baseline of travoprost 
ophthalmic solution 0.004%. After four weeks of adjunctive 
treatment, 56% of patients (n = 78) and 63% of patients after 
12 weeks (n = 71) had at least an additional 15% reduction 
in IOP.35
Reis et al randomized 52 eyes with open-angle glaucoma 
or ocular hypertension to receive adjunctive therapy of 
timolol 0.5%, brinzolamide 1%, or brimonidine tartrate 0.2% 
in conjunction with travoprost. Brinzolamide 1% and timolol 
maleate 0.5% showed greater IOP reduction compared with 
brimonidine 0.2%.36
The advantages of simpler dosing for topical glaucoma 
therapy can be better noticed in a regular daily-life environ-
ment than in clinical studies. This might be due to the fact 
that single-drop therapy is simple and flexible for patients, 
as well as the absence of the washout effect present with 
multiple-drop therapies. Moreover, maintenance of short- 
and long-term adherence to glaucoma medication regimens 
is better with a once-daily travoprost-timolol combination 
rather than with multiple-drop therapy.
As reported by Covert et al, 30.2% of patients treated 
with latanoprost 0.005% and 23.2% treated with bimatoprost 
0.03% required adjunctive treatment. Travoprost accounted 
for 22.5% of the adjunctive therapy.37 Netland et al reported 
that only 8% of patients treated with travoprost 0.004% 
needed adjunctive treatment.9
Safety of prostaglandin analogs
In studies to evaluate the relative incidence of hyperemia 
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incidence of hyperemia caused by latanoprost was 27.6%, 
while travoprost had a rate of 49.5%, and Cantor et al 
observed hyperemia in 21.1% of eyes treated with bimato-
prost and in 14.8% in eyes treated with travoprost.9,21 The 
use of travoprost 0.004% induced a conjunctival hyperemia 
incidence of 32.5%–49.5%, whereas timolol maleate 0.5% 
treatment had an incidence of 7%–14%.16
Hyperemia is usually mild and unlikely to interrupt 
clinical studies. In fact, improvement of hyperemia during 
continued dosing has been reported.10
Parrish et al found a higher incidence of hyperemia for 
bimatoprost, ie, 68.6%. Travoprost and latanoprost had a 
hyperemia incidence of 58% and 47.1%, respectively.20
It must be taken in consideration that the use of different 
methods for evaluation of hyperemia might be the cause of 
the significant variation of reported rates for conjunctival 
hyperemia, even for individual drugs. These methods have 
included patient complaints, tiered scoring systems used 
for subjective investigator grading of hyperemia, as well as 
photographic evaluation. Apart from the aesthetic adverse 
effects, conjunctival hyperemia has not been reported to be 
a major vision or health problem.
PGAs can also induce darkening of the iris, and its 
incidence in the literature varies according to the different 
methods used in its evaluation. Netland et al reported that 
iris hyperpigmentation was observed in 5.2% of eyes treated 
with latanoprost and in 3.1% in eyes treated with travoprost. 
Another study by Cantor et al in 157 subjects compared the 
effects of travoprost and bimatoprost, and iris hyperpig-
mentation developed in a single bimatoprost-treated eye.9,21 
Because of the fact that green and mixed hazel eyes are most 
affected by iris hyperpigmentation, the baseline eye color 
might influence the risk of developing this adverse effect. It 
was shown in a five-year study by Alm et al that over 75% 
of green-brown or yellow-brown eyes suffered iris hyper-
pigmentation after latanoprost treatment, while brown or 
blue/grey eyes were not affected.38 Overall, the incidence of 
iris hyperpigmentation caused by one year of daily treatment 
with travoprost 0.004% is low (less than 5%), and is con-
sidered to be a cosmetic issue rather than a harmful adverse 
effect with regard to either vision or health.16,38
The eyelashes can suffer some changes during treatment 
with travoprost and other PGAs. These drugs can induce 
eyelashes to increase in number and can cause alteration in 
their length, thickness, and darkness.16
A new preservative for travoprost, SofZia™ (Alcon 
Laboratories, Fort Worth, TX, USA), seems to offer better 
tolerability than benzalkonium chloride (BAK) for patients 
with ocular surface complaints. BAK-free travoprost was 
compared with latanoprost containing BAK preservative in 
patients with superficial punctate keratopathy. After replacing 
latanoprost containing BAK with travoprost containing 
SofZia, the score for superficial punctate keratopathy 
decreased significantly three months later.39,40
The integrity of the blood-aqueous barrier after prostaglan-
din treatment has been evaluated by Cellini et al. Cell and flare 
values of the anterior chamber were measured in 60 glaucoma 
patients who were randomly assigned to receive travoprost, 
latanoprost, or bimatoprost. A flare meter was used to quantify 
both cell and flare at baseline and after three and six months 
of therapy. The results showed significant increases in cell and 
flare from baseline at three and six months, and slight diminu-
tion of cell flare between three and six months of therapy for 
all three drugs, whereas significantly more cell and flare were 
induced by latanoprost at three and six months. After three 
months of therapy, travoprost induced more cell and flare than 
bimatoprost, and no significant difference between these two 
drugs was observed at six months.41
Similarly, in a crossover design, Arcieri et al studied the 
effect of these drugs in 34 phakic individuals. The patients 
received travoprost, latanoprost, and bimatoprost for four 
weeks, with a four-week washout between each drug. The drugs 
did not increase anterior chamber flare, nor did they induce 
differences in flare levels in a drug-dependent manner.42
The use of all three PGAs has been associated with 
macular edema, even though other risk factors for macular 
edema were already present, and usually prior to both 
complicated and uncomplicated cataract surgery. Macular 
edema resolved, and visual acuity returned to baseline after 
drug discontinuation. Macular edema is a rare outcome of 
travoprost or other PGA treatment. Its incidence is higher 
in pseudophakic eyes, and in eyes with other risk factors for 
macular edema, while probably no risk of macular edema can 
be implicated in phakic eyes without risk factors. Macular 
edema, as well as impaired visual acuity, can be resolved with 
interruption of PGA treatment.43–46 Notably, the cardiovas-
cular and pulmonary systems, and blood and urine are not 
considerably affected by travoprost treatment.16
Conclusion
IOP reduction is efficiently achieved by the PGAs. Among 
them, travoprost can lower IOP levels to 6.5–9.0 mmHg, 
being as effective as products combining timolol with 
latanoprost or dorzolamide. Other benefits of travoprost 
include probable increased efficacy in black patients, eyes 





glaucoma, and following cataract surgery. Even though the 
recommended dosing is once daily, travoprost can lower IOP 
up to 63 hours after the last dose, demonstrating greater IOP 
control at the end of each dose compared with latanoprost. 
Despite the development of minor adverse effects, such as 
conjunctival hyperemia, iris and eyelid hyperpigmentation, 
eyelash changes, and other rare cases of iritis and macular 
edema, which are common to PGA therapy, the efficiency 
and safety of travoprost have been extensively demonstrated. 
Moreover, convenient once-daily dosing has made travoprost 
a first-line therapy for glaucoma treatment and, in fixed 
combination with timolol, an option to enhance IOP control 
when monotherapy fails.
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